ViewMind develops digital cognitive biomarkers to accurately measure brain health and diagnose neurocognitive disorders. ViewMind’s technology combines VR, eye-tracking and AI, and has been independently validated by Tier 1 pharmaceutical companies and leading hospital facilities in randomized controlled trials. The initial commercial focus is improving outcomes for patients with multiple sclerosis, a group who has unmet clinical needs ViewMind can target.
Location: United States, New Jersey, Alpine
Employees: 11-50
Investors 2
| Date | Name | Website |
| 08.07.2022 | Creative D... | creativede... |
| - | R3i Capita... | r3icapital... |
Mentions in press and media 1
| Date | Title | Description |
| 09.08.2021 | ViewMind Announces Developer Agreement With HP to Help Revolutionise the Diagnosis and Treatment of Cognitive Disorders | Viewmind’s Award Winning Digital Biomarkers for Cognitive Disorders Combined With HP’s Leading Edge VR Technology, Paves the Way for a Global Societal Impact in Cognitive Health The medical device, digital health and artificial intelligence... |